PKC-IN-4

Cat. No.:	HY-147712
CAS No.:	2636771-29-2
Molecular Formula:	$C_{21}H_{25}N_5S$
Molecular Weight:	379.52
Target:	PKC
Pathway:	Epigenetics; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC_{50} of 0.52 μM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature[1].
IC_{50} & Target	PKC 0.52 μM (IC_{50})
In Vitro	PKC-IN-4 (compound 7l) shows VEGF - induced endothelial permeability with an EC_{50} of 0.071 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PKC-IN-4 (10 mg/kg for i.v.; 20 mg/kg for p.o.) shows orally active with oral bioavailability of 81.7%[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Animal Model: CD-1 mice[1]
Dosage:	10, 20 mg/kg
Administration:	10 mg/kg for i.v.; 20 mg/kg for p.o.
Result:	Showed good PK parameters with oral bioavailability of 81.7%.

REFERENCES

[1]. Liu X, et al. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. Bioorg Med Chem. 2020 Jun 1;28(11):115480.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA